Cancer diagnostics firm Exact Sciences' Q4 revenue rises

Overview

• Cancer screening firm's Q4 revenue rose 23%, beating analyst expectations

• Adjusted EBITDA for Q4 was $63 mln, affected by $75 mln R&D expense

Outlook

• Exact Sciences anticipates momentum from core products and portfolio expansion

• Exact Sciences' merger with Abbott expected to close in Q2 2026

Result Drivers

• SCREENING REVENUE - Screening revenue increased 26% to $695 mln, driven by Cologuard tests and PreventionGenetics

• PRECISION ONCOLOGY - Precision Oncology revenue rose 14% to $183 mln, supported by Oncotype DX and therapy selection tests

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 20 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Exact Sciences Corp is $105.00, about 1.7% above its February 12 closing price of $103.23

• The stock recently traded at 315 times the next 12-month earnings vs. a P/E of 270 three months ago

Press Release: ID:nBw9FlpYDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.